Understanding liver disease in alpha-1 antitrypsin deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how alpha-1 antitrypsin deficiency affects the liver over time. It aims to learn more about the disease and find better ways to monitor and treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of alpha-1 antitrypsin deficiency with the Pi*ZZ genetic type.
- You need to have medical records showing your health over at least 5 years, including liver check-ups.
- You must have had at least one liver test that measures stiffness and blood tests for liver scarring.
- You need to have stored blood samples available for research.
- You cannot have other liver diseases like hepatitis or a history of liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study screens for a rare genetic condition called Alpha-1 Antitrypsin Deficiency in people with lung blockage. It aims to find out if this deficiency is a hidden cause of your breathing problems, which could lead to better treatment options.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This study looks for a genetic condition called alpha-1 antitrypsin deficiency in people who have liver cancer (hepatocellular carcinoma) but do not have cirrhosis. If you have this deficiency, it might be the reason for your liver cancer, and the study may help identify more people with this condition.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
This study tests whether giving a protein called alpha-1 antitrypsin can help people with severe liver inflammation caused by heavy drinking. It may reduce the damage and improve recovery.
Hear when a new Alpha 1-antitrypsin Deficiency (AATD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.